8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Mendoza-Mari Y, Stojanovic M, Miulli DE, Agrawal DK

Bioeffects Seen

Authors not listed · 2025

Share:

Large surgical study shows extended blood clot prevention doesn't improve outcomes, highlighting importance of evidence-based medicine over theoretical benefits.

Plain English Summary

Summary written for general audiences

This large international study tracked over 11,000 patients after major abdominal surgery to see if extended blood clot prevention medication (28+ days) was effective and safe. Researchers found that post-surgery blood clots were rare (0.1%) and extended medication didn't significantly reduce clot risk or increase bleeding complications. The results suggest current short-term prevention may be adequate for most patients.

Why This Matters

While this study focuses on surgical outcomes rather than EMF exposure, it demonstrates an important principle we see repeatedly in EMF research: the gap between theoretical risk and measurable real-world outcomes. Just as this study found that extending blood clot prevention beyond standard protocols didn't provide clear additional benefit, we often see similar patterns with EMF mitigation strategies. The science shows that many everyday EMF exposures carry theoretical risks, but translating those into practical health interventions requires careful analysis of actual incidence rates and cost-benefit ratios.

This research methodology - large-scale, international, prospective cohort studies with clear outcome measures - represents the gold standard we need more of in EMF health research. Too often, EMF studies rely on small sample sizes or surrogate markers rather than tracking real clinical outcomes over time. When we do see this level of rigor applied to EMF research, the results often reveal that our everyday exposures may pose less immediate risk than laboratory studies suggest, though long-term effects remain an open question.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2025). Mendoza-Mari Y, Stojanovic M, Miulli DE, Agrawal DK.
Show BibTeX
@article{mendoza_mari_y_stojanovic_m_miulli_de_agrawal_dk_ce4147,
  author = {Unknown},
  title = {Mendoza-Mari Y, Stojanovic M, Miulli DE, Agrawal DK},
  year = {2025},
  doi = {10.1093/bjs/znaf005},
  
}
DOI: 10.1093/bjs/znaf005PubMed: 40067192

Quick Questions About This Study

No, the study found no significant reduction in blood clots when patients received extended anticoagulation (28+ days) compared to standard shorter treatment. Post-discharge clot rates were very low at just 0.1% overall.
The CASCADE study included 11,571 adult patients from 29 countries who underwent major abdominopelvic surgery between January and May 2022, making it a large international cohort.
Extended prophylaxis did not significantly increase bleeding risk. The study found a 0.7% bleeding rate overall, with no statistically significant difference between extended and standard treatment groups.
Modern surgical practices have made post-operative blood clots rare (0.1% incidence), creating a 'floor effect' where it's difficult to show additional benefit from extended prevention in low-risk populations.
The study suggests extended prophylaxis appears safe but clinical efficacy remains uncertain. Researchers concluded that further work is needed to identify which specific patients would benefit most.